▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #367 by analyst upside · 2026-11-13
LRMR
Larimar Therapeutics, Inc.
Healthcare · Market Cap $280M · P/E 0x
ANALYST PRICE TARGET
+433.3%
implied upside to consensus target
Current Price $2.7
Consensus Target $14.4
Bull Target $26.0
Bear Target $5.0
Analysts Covering 10
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
8
Hold
0
Sell
0
52-Week Low $1.92
52-Week High $6.42
YTD Return -22.2%
FUNDAMENTALS
Market Cap $280M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.99
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.92
52-Week High $6.42
Current Price $2.7
Bear Target $5.0
Bull Target $26.0
● Now $2.7 ● Target $14.4
TRADING DATA
Avg Volume 1.3M
YTD Return -22.2%
Analyst Count 10
Consensus Buy
Upside to Target +433.3%
Last Updated 2026-11-13

ANALYST SUMMARY

Larimar Therapeutics, Inc. (LRMR) is currently trading at $2.7 with a Wall Street consensus price target of $14.4, implying potential upside of 433.3% over the next 12 months. 10 analysts currently cover LRMR, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $26.0, while the most cautious has a target of $5.0.

LRMR operates in the Healthcare sector with a market capitalisation of $280M. The stock is down 22.2% year-to-date and is currently trading near the lower end of its 52-week range of $1.92 – $6.42.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for LRMR, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Wedbush - Reiterated
Outperform → Outperform 2026-08-05 Building track record
Baird - Reiterated
Outperform → Outperform 2026-06-30 Building track record
JP Morgan ● Initiated
Overweight 2026-05-27 43% win rate (7 calls)
Wedbush - Reiterated
Outperform → Outperform 2026-05-18 Building track record
Wedbush - Reiterated
Outperform → Outperform 2026-03-20 Building track record
Wedbush - Reiterated
Outperform → Outperform 2026-03-03 Building track record
Citigroup - Reiterated
Buy → Buy 2026-02-25 Building track record
Wedbush reit
Outperform → Outperform 2026-02-25 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
45
out of 100
Coverage depth
18/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →